~123 spots leftby Jan 2026

EGF Mapping and Ablation Therapy for Atrial Fibrillation

(RESOLVE-AF Trial)

Recruiting in Palo Alto (17 mi)
+30 other locations
KN
LB
Overseen byLucas Boersma
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Cortex
No Placebo Group

Trial Summary

What is the purpose of this trial?

Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.

Research Team

KN

Kent Nilsson, MD

Principal Investigator

Piedmont Athens Regional

LB

Lucas Boersma

Principal Investigator

St. Antonius Hospital

Eligibility Criteria

This trial is for adults who can legally consent and are suitable candidates for heart mapping and ablation therapy to treat various types of atrial arrhythmias, including different forms of atrial fibrillation, flutter, and tachycardia.

Inclusion Criteria

I am a good candidate for a procedure to correct irregular heartbeats.
I am over 18 years old or of legal age to consent where I live.

Treatment Details

Interventions

  • Ablacath™ Mapping Catheter (Procedure)
  • Ablacath™ Mapping Catheter Accessory Cables (Procedure)
  • Ablamap® System inclusive of Amplifier, Monitor/Workstation with installed Ablamap® Software (Procedure)
Trial OverviewThe trial tests the Ablacath™ Mapping Catheter and Ablamap® System's safety and effectiveness in creating Electrographic Flow (EGF) maps to guide treatment for all types of atrial fibrillation during initial or repeat procedures.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Redo Arm: Electrographic Flow (EGF) mapping and guided ablation of EGF-identified sourcesExperimental Treatment1 Intervention
Subjects with paroxysmal, persistent or long-standing persistent atrial fibrillation (AF) coming in for a redo AF procedure.
Group II: De Novo Arm: Electrographic Flow (EGF) mappingExperimental Treatment1 Intervention
Subjects with persistent or long-standing persistent atrial fibrillation (AF), coming in for a De Novo pulmonary vein isolation procedure.

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
University of VirginiaCharlottesville, VA
University of Illinois HealthChicago, IL
Ohio State UniversityColumbus, OH
Evergreen Health Research/Overlake Medical CenterBellevue, WA
More Trial Locations
Loading ...

Who Is Running the Clinical Trial?

Cortex

Lead Sponsor

Trials
2
Patients Recruited
490+

Ablacon, Inc.

Industry Sponsor

Trials
4
Patients Recruited
600+